pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,259 catalysts · 4,970 phase readout · 2,357 8k filing · 287 earnings · 276 pdufa · 129 phase 2 completion · 61 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 28 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: approval×type: earnings×type: phase readout×clear all
type
  • phase readout4,970
  • 8k filing2,357
  • earnings287
  • pdufa276
  • phase 2 completion129
  • phase 1 completion61
phase 1 initiation
32
  • phase 1 2 completion28
  • phase 0 trial completion22
  • phase 2 initiation16
  • therapy area

    no tagged catalysts yet

    Date TBD

    50
    ›COMPLETEDphase readoutNCT07469865: Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)

    Sponsor: University Hospital, Ghent. Phase: NA. Conditions: Dry Eye Disease

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02553967: Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO)

    Sponsor: Centre Oscar Lambret. Phase: NA. Conditions: Breast Cancer

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT02537067: Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle

    Sponsor: Cellontech Co., Ltd.. Phase: PHASE3. Conditions: Defect of Articular Cartilage, Degenerative Joint Disease of Ankle and/or Foot, Ankle (Ligaments); Instability, Familial

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07405567: Ultrasound Evaluation of Respiratory Muscles During Mechanical Ventilation Weaning in ICU Patients

    Sponsor: Bursa Sevket Yilmaz Training and Research Hospital. Phase: . Conditions: Pneumonia, Invasive Mechanical Ventilation, Weaning From Mechanical Ventilation in Care Unit, Respiratory Muscle Dysfunction

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05482867: Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells

    Sponsor: MindImmune Therapeutics, Inc.. Phase: . Conditions: Probable Alzheimer's Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06572267: Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

    Sponsor: Xijing Hospital. Phase: PHASE2. Conditions: Coronary Artery Disease

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07596407: Acute Kidney Injury : Long-term Renal and Cardiovascular Prognosis and Biomarker-based Risk Assessment

    Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: . Conditions: Renal Injury, Acute

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07222007: Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients

    Sponsor: Zeliha Alicikus. Phase: . Conditions: Critically Ill, Intubation Complication, Oxygenation, Airway Management, Propofol, Ketamine

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06390592: Clinical Performance of the Therapy Option FlexPoint of the PD Cycler Sleep•Safe Harmony

    Sponsor: Fresenius Medical Care Deutschland GmbH. Phase: NA. Conditions: Renal Failure, Chronic Kidney Disease

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT02793492: Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery

    Sponsor: Terumo Medical Corporation. Phase: NA. Conditions: Iliac Artery Stenosis

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07656792: A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood

    Sponsor: Boehringer Ingelheim. Phase: PHASE1. Conditions: Healthy

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06239792: Sleep Promotion Program Primary Care (SPP PC) Open Trial

    Sponsor: University of Pittsburgh. Phase: NA. Conditions: Sleep, Sleep Disturbance, Insufficient Sleep

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07586592: Comparison of Age-Based Formula and Ultrasound-Guided Subglottic Diameter Measurement for Endotracheal Tube Sizing

    Sponsor: Ain Shams University. Phase: NA. Conditions: Endotracheal Tube Wrongly Placed During Anesthetic Procedure

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04491292: Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce

    Sponsor: M.D. Anderson Cancer Center. Phase: . Conditions: COVID-19 Infection

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05429892: FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers

    Sponsor: University of Arkansas. Phase: NA. Conditions: Tobacco Cessation, Tobacco Dependence, Food Security

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07524036: Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan.

    Sponsor: University Hospital, Bordeaux. Phase: NA. Conditions: Stroke, Patient Education

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05978622: Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

    Sponsor: AbbVie. Phase: . Conditions: Diabetic Macular Edema

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07493629: Immune Status and Disease Control of Inflammatory Airway Diseases

    Sponsor: First Affiliated Hospital of Ningbo University. Phase: . Conditions: Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis, OSAS (Obstructive Sleep Apneas Syndrome), Allergic Bronchopulmonary Aspergillosis (ABPA)

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06335329: Point-of-Care Ultrasound (POCUS) Findings and Impact on Vaping

    Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Vaping

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06856902: BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe

    Sponsor: Technical University of Madrid. Phase: NA. Conditions: Cardiovascular Diseases, Endocrinology, Inmunology, Neurology, Oncology, Rare Diseases

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05831202: SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial

    Sponsor: Galaxy Therapeutics INC. Phase: PHASE3. Conditions: Intracranial Aneurysm

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06647602: Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

    Sponsor: University Medical Center Groningen. Phase: . Conditions: Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine, Liothyronine, Thyroid Hormones

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03969953: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

    Sponsor: The George Institute. Phase: PHASE3. Conditions: Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

    Sponsor: EMD Serono Research & Development Institute, Inc.. Phase: PHASE1. Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03364153: Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

    Sponsor: Astellas Pharma Global Development, Inc.. Phase: PHASE2. Conditions: Stargardt's Macular Dystrophy

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07418372: Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine

    Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences. Phase: PHASE1. Conditions: Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria, Pertussis, Pertussis Vaccines

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06361472: Contextual Factors-Enriched Standard Care on Mechanical Neck Pain

    Sponsor: Universidad Nacional de la Matanza. Phase: NA. Conditions: Neck Pain

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06079372: Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

    Sponsor: Alexion Pharmaceuticals, Inc.. Phase: PHASE3. Conditions: Hypophosphatasia

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07112495: Maternal Burnout, Breastfeeding Self-Efficacy and Attachment Level

    Sponsor: Sakarya University. Phase: NA. Conditions: Pregnancy

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07360639: The Effectiveness of Herbal Creams Compared to Urea in Dry Skin Treatment

    Sponsor: Universitas Syiah Kuala. Phase: PHASE1. Conditions: Dry Skin, Xerosis Cutis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07368777: Comparison of Genotype-Based Dietary Counseling Versus Standard Dietary Counseling on Weight Loss and Fat Mass Reduction

    Sponsor: Metropolitan College. Phase: NA. Conditions: Overweight, Overweight and Obesity, Adiposity

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07684677: Effect of Participating in a Study of Causes of Pregnancy Loss on Mental Health Outcomes: A Target Trial Emulation Using the COPL Cohort and Danish National Registries

    Sponsor: Amager Hospital. Phase: NA. Conditions: Pregnancy Loss, Early, Major Depression, Anxiety, Stress (Psychology)

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03485677: Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

    Sponsor: Sanofi. Phase: PHASE3. Conditions: Gaucher's Disease Type I, Gaucher's Disease Type III

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05608577: RE-BLEED: A Digital Platform for Identifying Bleeding Patients - a Feasibility Study

    Sponsor: University of Oxford. Phase: . Conditions: Hemorrhage, Trauma, Gastro Intestinal Bleeding

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07566377: Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: PHASE2. Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia, Lymphoma, Graft-versus-host Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04892277: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

    Sponsor: Mayo Clinic. Phase: PHASE1. Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06933875: Promoting Palliative Care for People With Heart Failure

    Sponsor: Yale University. Phase: NA. Conditions: Heart Failure, Palliative Care

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07615257: Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control

    Sponsor: Islamia University of Bahawalpur. Phase: NA. Conditions: Psoriasis

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06087757: Clemastine Treatment in Individuals With Williams Syndrome

    Sponsor: Sheba Medical Center. Phase: PHASE2. Conditions: Williams Syndrome

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05994001: Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

    Sponsor: Shanghai Zhongshan Hospital. Phase: PHASE1. Conditions: Biliary Tract Cancer, Candonilimab, Claudin 18.2

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06957301: Intrathecal Fentanyl and Dexmedetomidine Added to Bupivacaine for Subarachnoid Anaesthesia for Percutaneous Nephrolithotomy

    Sponsor: Alexandria University. Phase: NA. Conditions: Percutaneous Nephrolithotomy (PCNL)

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06533501: Leucine Requirements During the Menstrual Cycle

    Sponsor: University of British Columbia. Phase: NA. Conditions: Menstrual Cycle

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05608681: A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

    Sponsor: Eupraxia Pharmaceuticals Inc.. Phase: PHASE1. Conditions: Eosinophilic Esophagitis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03588481: IRIS- DESyne X2 in the IRIS-DES Registry

    Sponsor: Seung-Jung Park. Phase: . Conditions: Coronary Stenosis, Coronary Occlusion, Coronary Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06558981: Adjuvant Radiotherapy in High Risk Locally Advanced DTC

    Sponsor: Fudan University. Phase: PHASE3. Conditions: Thyroid Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06183281: Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity

    Sponsor: University of California, San Francisco. Phase: NA. Conditions: Chronic Pain

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07647081: The Impacts of Ashwagandha Supplementation on Diurnal Cortisol and Stress Among Women

    Sponsor: Oklahoma State University Center for Health Sciences. Phase: NA. Conditions: Stress

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07470619: Meditation for Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer

    Sponsor: Near East University, Turkey. Phase: NA. Conditions: Nausea and Vomiting Chemotherapy-Induced, Meditation Training

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT03730467: Puncture Breast Abscess

    Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: . Conditions: Breast Abscess

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04093167: Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

    Sponsor: Canadian Cancer Trials Group. Phase: PHASE2. Conditions: Lung Cancer

    full page →ctgov ↗
    ← prev
    page 84 of 106
    next →